



Carolina Salcedo Roca

+34 680340153



<https://www.linkedin.com/in/carolina-salcedo-roca-42512018/>



info@csalcedopharma.com

Core Strengths

Drug Discovery
Integrative Vision

Create and Inspire
Teams

Skills & Endorsements

Drug Discovery &
Development
(Preclinical → Phase 3)

Regulatory Strategy
Support (FDA/EMA
IND/NDA)

Scientific Due Diligence
& Investor
Presentations

Cross-functional Team
Leadership

My Ikigai

To find the joy in what
you do

Project success is
based on the Team

To live in
collaboration &
respect

To never lose
curiosity

Contribution to science - Key Achievements

- 15 international patents | 21 peer-reviewed publications | 70+ scientific presentations
- Contributed to 4 approved drugs: Cetraxal, Eberconazole, Ebastine, Almotriptan
- Led SNF472 from discovery through Phase 3 clinical trials
- Directed preclinical & clinical strategy for biotech firms transitioning to pharma partnerships
- Coordinated multidisciplinary teams across Europe and the U.S. (internal + CROs/KOLs)

Professional Experience

- PhD Pharmacologist with 35+ years involved in driving innovation in pharmaceutical and biotech R&D—from first-in-class discoveries to regulatory approvals
- Specialized in building scientific strategies that bridge early research and clinical application, with deep expertise in pharmacology, toxicology, ADME/PK-PD, and regulatory science
- Proven track record from bench to bedside: led projects from molecule identification to Phase 3 trials and market approval. Involved in five Phase 1, five Phase 2 and 1 Phase 3 clinical trails
- Contributor to 20+ drug development programs, with 4 products commercially available (Cetraxal, Almotriptan, Ebastine, Eberconazole)
- Working at Sanifit Therapeutics for the last 13 years, in charge of a great team who brought SNF472, a first in class vascular calcification inhibitor, from concept to Phase 3 trials, involving MOA characterization, non-clinical regulatory package (IND) and clinical development till NDA
- Biotech company support on two fronts—fundraising and scientific—by creating value and presenting the project to the board of directors, investors, key opinion leaders (KOLs), and at scientific events

Professional Career

YEARS	POSITION, PLACE
2025 – to date	Discovery and Development Consultant
2022 – 2025	Head of Scientific Strategy Sanifit CSL, Barcelona/Mallorca
2014 – 2022	Chief Scientific Officer, Sanifit Laboratories, Barcelona/Mallorca
2011 – 2014	Director of Pharmacology, Sanifit Laboratories, Barcelona/Mallorca
2009 – 2011	Project Manager, PalauPharma /Uriach, Barcelona
1998 – 2008	Head of Pharmacology &Toxicology, Lab SALVAT, Barcelona
1991 – 1998	Program leader, Almirall, Barcelona
1989 – 1991	Pharmacologist, Wasserman (Chiesi), Barcelona

Education

INSTITUTION&SITE	DEGREE	YEAR	FIELD OF STUDY
Universidad Barcelona, Spain	BA	1989	Biology
Universidad Autonoma, Barcelona, Spain	MA	1995	Neuroscience
Universidad de Sevilla, Sevilla, Spain	MA	2002	Toxicology
Universidad Autonoma, Barcelona, Spain	PHD	2008	Pharmacology